glp-1 for ibs-d TrimRX When it comes to GLP-1s,

Second, the off-label adoption pattern that the longevity reframing will inevitably accelerate is going to produce the next wave of monitoring, dosing, and selection problems, patients without obesity or diabetes do not have the diagnostic anchors (BMI, A1c, insulin resistance markers) that frame the on-label conversation, and the clinical infrastructure for managing GLP-1 therapy in metabolically healthy users is, charitably described, thin

,

To quantify peptide level, the intensity of the peptide lacking L585 was compared to that of the peptide containing L585 within the same sample

When inflammation stays high, tissue repair can slow

Tiffany Truong is a resident physician in internal medicine in Houston and a member of the ABC News Medical Unit.

~15% of patients admitted to the ICU for status epilepticus may have pseudoseizure